Tilray Brands (TLRY)
(Delayed Data from NSDQ)
$1.77 USD
-0.02 (-1.12%)
Updated Jun 7, 2024 04:00 PM ET
Pre-Market: $1.77 0.00 (0.00%) 8:22 AM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Tilray Brands, Inc. [TLRY]
Reports for Purchase
Showing records 81 - 100 ( 219 total )
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
The New Tilray with Shares to Execute Growth, Remain Neutral, New $12 PT
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Weekly Comps - September 8 th September 13 th , 2021
Provider: Beacon Securities Ltd.
Analyst: COOPER D
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
4Q21 Initial Thoughts on 1st Quarter as Merged Entity, U.S. Expansion Key
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
A Day of Progress for Cannabis Legislative Reform
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Expectations of Schumer''s Legalization Plan
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Weekly ReHash: 50th Anniversary of Cannabis Prohibition, Conversion Takes Time
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
1Q21 Week II Earnings Preview: Expect U.S. MSO and Ancillary Strength
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
1Q21 Earnings Week I Preview: 1Q Muted By COVID/Seasonality, 2H21 Acceleration
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Cannabis State of the Union: Legislative Tailwinds & Positioned for 2H Strength
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
The Weekly Rehash: NY and NM Legalize Cannabis and Another Round of M&A
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
4Q20 Solid Progress Ahead of Merger, Raise PT $25 on Pro Forma 2022
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S